Barbara Mackie and Jo Lenton
Community Specialist Palliative Care
• Breathlessness is an uncomfortable sensation or
awareness of breathing.
• Subjective – measuring lung function does not correlate
with sensation or severity of breathlessness
• A complex experience of mind and body that is likely to
progress with disease severity
• Significant correlation with impaired quality of life and poor
survival. Effects Patients and Carers.
• A common complex distressing symptom at the end of life
Prevalence of Breathlessness in cancer
• The prevalence of breathlessness varies with the
primary tumour site;
• Breathlessness occurs as a symptom most frequently in
lung cancer, where it might affect 75% of people with
primary disease of the lung, bronchus and trachea
(Muers & Round 1993).
Breathlessness in non-malignant disease
• For patients with COPD, intractable breathlessness
develops late in the course of the disease, gradually
increasing in severity over a period of years in the
majority of people.
• There is a long pre-clinical phase when patients may not
have any respiratory symptoms at all, although lung
damage exists.
Breathlessness in non-malignant disease
• There is then a protracted period of gradual decline
punctuated by severe exacerbations, which may be lifethreatening and require inpatient management.
• Breathlessness tends to be associated with exertion.
• However at end of life it may be present at rest.
• What are the Causes of
Psychological Aspect of
Assessment of breathlessness
What does it mean to the patient / carer?
Triggers / What eases it?
Levels of significance – during activity, in
different positions, at rest
Pattern of breathing, colour, respiratory rate
Are they anxious?
Oxygen saturations
Manage reversible causes optimally
according to patients wishes
Consider active treatment of:
Pleural effusion
Airway obstruction SCVO
Non Pharmacological
Airflow - use of fan /window
Relaxation / Distraction/ Reassurance
Energy conservation / Pacing
Controlled Breathing techniques /physio
Loose clothing
Mouth Care
Comfortable Positions if short of breath
Breathing Techniques
• Start with position of ease
• Relax shoulders / upper chest
• Diaphragmatic ‘tummy’ breathing
• Breath out twice as long as breath in
• Pursed lips on breathing out if needed
Time and calm environment essential
Relax and Breathe CD
Visual imagery
‘Calming hand’
Touch across back
. Pacing activities
Encourage activity
Allow time for tasks
Starting and stopping with rest intervals
Inspiration: expiration ratio during activity
Use of aids – stair lift etc
Adapting functional tasks, e.g. Ironing sitting
Pharmacological Management
• Opioids
• Opioids are the most effective pharmacological agents
for the relief of dyspnoea
• Oral morphine (normal release) 2.5mg (if Opioid
naive/elderly and renal impairment)
• Gradual titration upwards according to response
• High level evidence supports:
• Low dose slow release oral morphine for opioid naïve
• .
Pharmacological management
• Benzodiazepines
• Lorazepam 0.5-1mg sublingual (SL) - rapid relief during
panic attacks
• Diazepam (oral) for longer term management
• Midazolam 2.5mg subcutaneous 5 -10mg in Syringe
driver over 24hrs
• Above medication are sedative, therefore should be monitored
carefully. However in the terminal stages of illness the benefits
usually out-weigh the risks.
Pharmacological Management
• Oxygen therapy only where appropriate (mixed
evidence, check sats if hypoxic resting O2 below 90%
• Steroids
• Bronchodilators nebulised (Salbutomol 2.5 5mg prn)
• Antibiotics
• Nebulised saline to thin secretions or Carbocisteine if
secretions difficult to expectorate and exacerbating
breathing difficulties
• Blood transfusion
End of life secretions
• Often referred to as ‘death rattle’
• Caused when a patient’s coughing and
swallowing reflex is impaired or absent, causing
fluids to collect
• Not easily relieved by drug therapy once
• Treatment should therefore be started at first
sign of rattle
Non-pharmacological management of
• Re-positioning of the patient by tilting side to side, or tipping bed
‘head up’ to reduce noise
• Management of halitosis with frequent mouth care and
• Discrete management of oral secretions mouth care – oral hygiene
• Suction not advised, except when secretions are excessive
• Reassurance to family that the noise is due to secretions, and not
causing suffocation, choking or distress
• Reduce oral fluids if at risk of aspiration
Pharmacological management of
Hyoscine Butylbromide (Buscopan)
60- 240mg/24hr s/driver, prn dose SC 20mg hrly
If not effective, discuss with palliative care team who may consider -
Glycopyronium Bromide (Glycopyrolate)
400-2400mcg/24hr s/driver or prn dose 200mcg
NB: Hyoscine Hydrobromide was historically drug of choice, but not
currently recommended due to side effects of sedation and confusion
• DAVIS.C(1998) Breathlessness,cough and other
respiratory problems.In: FALLON.N.O’NEILL.B(eds)ABC
of Palliative Care BMJ Books. London pp 8-15
• MUERS.M. ROUND.C (1993)Palliation of symptoms in
Non –Small Cell Cancer:A Study by the Yorkshire
Regional Cancer Organisation Thoracic Group.
Thorax.48 (7) 339-349
• Sheffield Palliative Care Formulary 3rd Edition
Thank you for listening
Related flashcards


48 cards

Tumor markers

15 cards

Cancer hospitals

29 cards

Oncology journals

71 cards

Cancer researchers

69 cards

Create Flashcards